Yondelis approved in Russia for STS
Russian regulators have approved Yondelis (trabectedin) for the treatment of soft tissue sarcoma in adults, following its clearance in STS in Europe in September 2007. Under the licensing agreement with US health care major Johnson & Johnson, the drug's originator, Spanish firm PharmaMar, will receive royalties on sales of the agent in Russia. According to the terms of the deal, PharmaMar, which is part of the Zeltia group, has rights to market the compound in Europe and Japan, while J&J subsidiary Ortho Biotech Products has marketing rights in the rest of the world. Yondelis is currently being sold in the European Union for the treatment of STS in adults after the failure of standard therapy. PharmaMar plans to submit a Marketing Authorization Application for Yondelis for the treatment of ovarian cancer to the European Medicines Agency (EMEA) this month.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze